#Canaccord

2 stories

Industry May 15, 2026 · View digest

Hims & Hers Closes Week -13% Post-Q1; Motley Fool May 14 Frames the Dip as a Buying Opportunity

Hims & Hers shares fell ~13% after the May 11 Q1 print as $608.1M revenue missed the $616.9M consensus and gross margin compressed from 73% to 65% on the compounded-semaglutide wind-down. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed); Canaccord raised to $32 from $30 (Buy). The Motley Fool published a 'Is HIMS Stock a Buy After Latest Dip?' analysis on May 14 framing the post-print decline as a buying opportunity, citing the 9% subscriber growth to 2.6M, the raised full-year guide ($2.8-3.0B revenue, $275-350M Adjusted EBITDA), and the structural lift from the Novo Nordisk branded-Wegovy distribution deal landing in Q2 books. The split between bullish and cautious analyst takes captures the central tension: high-growth telehealth navigating a margin-dilutive product transition.

Industry May 14, 2026 · View digest

JPMorgan Cuts Hims & Hers Price Target to $33; Canaccord Raises to $32 — Split Calls on Post-Q1 GLP-1 Pivot

Wall Street's read of Hims & Hers' Q1 print delivered May 11 split between two camps. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed) on what analysts called a 'mixed' quarter, citing gross margin compression from 73% to 65% on the wind-down of compounded semaglutide. Canaccord raised its target to $32 from $30 (Buy) framing the quarter as a transition speed bump rather than a thesis break. The central question both calls land on: whether branded Novo Nordisk Wegovy/Ozempic distribution (live since March 26) can offset margin loss from the compounded business. Q1 books closed March 31, so meaningful Wegovy revenue contribution comes in Q2; subscriber count held at 2.6M (+9% YoY).